Drug Development Pipeline
This program studied pravibismane, an inhaled antibiotic. In the lungs of people with CF, bacteria may form protective layers -- known as biofilms -- that make them more difficult to kill. Pravibismane was studied for the potential to help break down biofilms and kill drug-resistant bacteria, such as multi-drug resistant Pseudomonas aeruginosa.
No further development in CF is planned at this time.
This program was sponsored by Microbion and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More